Vol. 5 No. 8 (2025)
Reimbursement Recommendations

Durvalumab (Imfinzi)

decorative image of the issue cover

Published August 27, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Imfinzi be reimbursed by public drug plans for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiotherapy (CRT), if certain conditions are met.
  • Imfinzi should only be covered to treat adults with LS-SCLC (stage I to III) who have not experienced disease progression after receiving platinum-based CRT. Patients must have completed 4 cycles of CRT and must be in relatively good health (as measured by performance status).
  • Imfinzi should only be reimbursed if it is prescribed as monotherapy, by a clinician with expertise in treating lung cancer and immunotherapy, and if the cost of Imfinzi is reduced. Treatment should be stopped if the cancer gets worse, its side effects become too severe, or after 24 months of therapy.